GFAP, another biomarker used as diagnostic instrument in the setting of neuroinflammation and recently FDA-approved for mild traumatic brain injury,34 had no added value in our model to separate CALD from asymptomatic X-ALD patients. This evidence concerns the gene GFAP and X-linked adrenoleukodystrophy.